Dynavax Technologies Corporation (NASDAQ:DVAX) surged 8% Thursday following the announcement of encouraging topline data from ...

The company said that it now intends to advance Z-1018 into the next part of the study in adults 70 years of age and older in ...

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in ...

Shares of Dynavax rose after the company released positive results from a trial of its shingles vaccine tested against current Shingles vaccine Shingrix. The stock was up 6.7% to $11.12 but is still ...

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Dynavax beats Q2 expectations with Heplisav-B driving growth. Click here for a full investment analysis of DVAX stock.

Key Points Dynavax Technologies (NASDAQ:DVAX) exceeded analyst expectations in Q2 2025, reporting GAAP revenue of $95.4 million and GAAP diluted EPS of $0.14. HEPLISAV-B, Dynavax's two-dose adult ...

Dynavax share price gained 178% between the end of April and mid-July, to trade at $11.8 - its highest level since January 2019, when the company's main focus was on progressing its portfolio of ...

Dynavax Technologies Corporation announced today that the U.S. Food and Drug Administration has accepted for review Dynavax's responses to the Complete Response Letter issued by the FDA in ...

Since December, Dynavax's stock price has been hovering largely in the 2.50-$3 range, but slowly creeping up in anticipation of the upcoming FDA approval decision date for Heplisav on Feb. 24. Let ...